RxDoctor Payments Data

Liliya Gandrabur, MD

Rheumatology · Bronx, NYNPI 1811377989

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 39 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$322
  • AbbVie$226
  • Janssen Scientific Affairs, LLC$149
  • AstraZeneca$102
  • Lilly USA, LLC$80
  • Aurinia Pharma U.S., Inc.$68
  • plus $88 from 2 others

What the payments were for

  • Food & beverage$98195%
  • Education$555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 40th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$2,927
Medicare patients
19
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept134$936,917
OrenciaAbatacept/Maltose69$355,003
Humira(Cf) PenAdalimumab29$202,784
Orencia ClickjectAbatacept33$179,011
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$139,628
Taltz AutoinjectorIxekizumab21$139,350
Taltz Autoinjector (2 Pack)Ixekizumab11$138,947
Humira(Cf)Adalimumab21$136,068
Cimzia (2 Pack)Certolizumab Pegol13$128,474
Xeljanz XrTofacitinib Citrate14$75,791
Diclofenac Sodium ErDiclofenac Sodium626$47,135
RasuvoMethotrexate/Pf40$24,348
ProliaDenosumab14$22,284
OtrexupMethotrexate/Pf23$16,512
MethotrexateMethotrexate Sodium200$3,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$226$136,06821 claims
AmgenProlia$322$22,28414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 541 rheumatology providers in New York.

Other rheumatology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →